A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients

Abstract Objective Anlotinib is a multitarget anti-angiogenic drug that combined with temozolomide (TMZ) can effectively prolongs the overall survival (OS) of recurrent malignant glioma(rMG),but some patients do not respond to anlotinib combined with TMZ. These patients were associated with a worse...

Full description

Bibliographic Details
Main Authors: Yurong Li, Weilin Xu, Yinjiao Fei, Mengxing Wu, Jinling Yuan, Lei Qiu, Yumeng Zhang, Guanhua Chen, Yu Cheng, Yuandong Cao, Shu Zhou
Format: Article
Language:English
Published: Springer 2023-08-01
Series:Discover Oncology
Subjects:
Radiomics mode
Anlotinb
Temozolomide
Recurrent malignant glioma
Online Access:https://doi.org/10.1007/s12672-023-00751-x

Internet

https://doi.org/10.1007/s12672-023-00751-x

Similar Items